InvestSMART

Microba Life Sciences Limited (ASX:MAP)

ALERT: Price-sensitive ASX Announcement for MAP
Current share price for MAP : $0.048 0.007 (17.07%)+
Announcement
Release
16 Jul 2026 9:12AM
Price at Release
$0.041
Full Release
download
Summary
Microba Life Sciences Limited reported substantial growth in its core testing services for Q4 FY26, including a 54% year-on-year increase in Microbiome Explorer test sales in Australia and a 92% increase in the UK. The company emphasized expanding enterprise accounts and plans to launch the GI Navigator, a new diagnostic product, in September 2026. The Invivo supplements segment also showed significant growth. The company is actively engaging in partnerships for its therapeutic assets, with plans to reach break-even by CY2027. Microba remains focused on leveraging its databank for therapeutic development and diagnostics expansion in the UK and Australia.
Key Points
  • Q4 FY26 Microbiome Explorer AU test sales up 54% year-on-year.
  • UK Microbiome Explorer test sales increased by 92%.
  • GI Navigator, a new diagnostic product, set for September 2026 release.
  • Significant growth in Invivo supplements with PHGG sales doubling.
  • Active therapeutic asset partnerships, leveraging extensive databank.
  • Enterprise accounts grew, targeting 24,000 test annual potential.
  • Aim for break-even by CY2027 with strategic cost base reduction.
  • Continued progress in diagnostics in Australia and the UK.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.